Matinas BioPharma Holdings (MTNB) Research & Development (2013 - 2025)
Matinas BioPharma Holdings (MTNB) reported Research & Development of $85000.0 for Q1 2025, down 97.53% year-over-year from $3.4 million in Q1 2024, and down 96.42% quarter-over-quarter from $2.4 million in Q4 2024.
Matinas BioPharma Holdings (MTNB) Research & Development (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 13 years of Research & Development data on file, last reported at $85000.0 in Q1 2025.
- Research & Development for Q1 2025 came in at $85000.0, down 97.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $85000.0 (down 99.26% YoY), and the FY2025 annual result was $85000.0, down 99.26% from the prior year.
- Research & Development fell to $85000.0 in Q1 2025 per MTNB's latest filing, from $2.4 million in the prior quarter.
- Over five years, Research & Development peaked at $5.0 million in Q1 2022 and troughed at $85000.0 in Q1 2025.
- A 5-year average of $3.4 million and a median of $3.6 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development soared 66.36% in 2022, then plunged 97.53% in 2025.
- A 5-year view of Research & Development shows it stood at $4.2 million in 2021, then slipped by 8.79% to $3.9 million in 2022, then declined by 5.22% to $3.7 million in 2023, then plunged by 35.17% to $2.4 million in 2024, then tumbled by 96.42% to $85000.0 in 2025.
- Business Quant data shows MTNB's Research & Development at $85000.0 in Q1 2025, $2.4 million in Q4 2024, and $2.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | 2.38 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 3.87 Mn |
| Sep 30, 2022 | 3.71 Mn |
| Jun 30, 2022 | 4.13 Mn |
| Mar 31, 2022 | 4.98 Mn |
| Dec 31, 2021 | 4.24 Mn |
| Sep 30, 2021 | 4.62 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 3.24 Mn |
| Dec 31, 2020 | 3.53 Mn |
| Sep 30, 2020 | 3.34 Mn |
| Jun 30, 2020 | 3.41 Mn |